Abbott

March 27, 2020

Dear Customer:

At Abbott, our mission is to help people live healthier lives. As a leader in diagnostic testing, we have a unique responsibility to contribute our expertise to help fight the COVID-19 pandemic. And we are eager to do our part.

Abbott recently announced that we have received Emergency Use Authorization from the U.S. Food and Drug and Administration for a COVID-19 test for use with our ID NOW rapid point-of-care platform.

Abbott is working to prioritize delivery of COVID-19 tests to hotspots in the U.S. where the tests are needed most – including hospital emergency departments and urgent care centers. While we are running at full capacity, day and night, to manufacture ID NOW COVID-19 tests, we may not be able to fulfill all purchase requests.

Furthermore, because we have dedicated our ID NOW test manufacturing capacity to making COVID-19 tests, we may experience supply interruptions on our Influenza A&B, Strep A and RSV tests used on the ID NOW platform. We prioritized the greater good of meeting critical COVID-19 testing needs during these extraordinary times.

As this situation evolves, we hope to bring ID NOW Flu, Strep and RSV test manufacturing back online as quickly as possible. You have our commitment to work closely with you on ID NOW COVID-19 inventory availability and to offer alternative Influenza A&B, Strep A and RSV tests from our lateral flow portfolio.

Please reach out to your local sales representative, our Global Services Team at 1-877-441-7440 or via email COVIDService@abbott.com with any questions, as we work to help you care for your patients.

We appreciate your patience and understanding as we work together through this situation.

Sincerely,

Jeff Haas

Vice President, Infectious Disease, Developed Markets
Abbott Rapid Diagnostics

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.